abemaciclib

Verzenio is classified as a targeted treatment, not a chemotherapy drug, and may be prescribed for specific forms of breast cancer. It falls under the category of CDK 4/6 inhibitors, which work to decrease the proliferation and dissemination of cancer cells within the body.

Hair thinning or loss was observed in 12% to 27% of patients who were administered Verzenio. The highest incidence of hair thinning or loss, at 27% of patients, was observed in those who were taking Verzenio in combination with an aromatase inhibitor like letrozole or anastrozole.

Abemaciclib has received an average rating of 8.2 out of 10 based on 17 reviews for the treatment of Breast Cancer. Among the reviewers, 65% had a positive experience, while 6% had a negative experience.

While taking abemaciclib, it is important to avoid consuming grapefruit or grapefruit juice as it can interfere with the effectiveness of the medication. If you happen to miss a dose, simply take the next one at your regular scheduled time and do not take a double dose.

The most commonly reported adverse effects (AEs) in the patients were anemia, increased blood creatinine levels, diarrhea, and neutropenia, with percentages of 90%, 83%, 83%, and 75% respectively.

If you experience pain or tenderness in the upper stomach, pale stools, dark urine, loss of appetite, nausea, vomiting, or yellow eyes or skin, it is important to consult your doctor immediately as these could indicate a serious liver problem. Additionally, please be aware that taking this medication may heighten your risk of developing blood clots, which can be potentially life-threatening.

Verzenio has the potential to result in blood clots in your veins or lungs’ arteries, which can be severe and fatal. If you experience blood clots while taking Verzenio, your healthcare provider may advise you to discontinue its use temporarily.

Women with high-risk oestrogen responsive (HR-positive), HER2-negative breast cancers that have at least 4 involved axillary lymph nodes, or 1-3 involved nodes and meet at least one of the following criteria – tumour size of at least 5 cm or histological grade 3, are eligible for the drug.

For early breast cancer, Verzenio is typically taken for 2 years, while for advanced or metastatic breast cancer, it is taken long term. The medication is continued until it is no longer tolerable or until the condition deteriorates.

If you have primary breast cancer, the usual duration for taking abemaciclib is two years, in combination with hormone therapy.

While taking abemaciclib, it is important to avoid consuming grapefruit or grapefruit juice as it can interfere with the effectiveness of the medication. If you happen to miss a dose, simply take the next one at your regular scheduled time and do not take a double dose.

Verzenio combined with fulvestrant resulted in a significant increase in overall survival for women compared to fulvestrant alone. According to a clinical study, women who received Verzenio plus fulvestrant had a median survival of 46.7 months, while those on fulvestrant alone had a median survival of 37.3 months, regardless of their menopausal status.

Abemaciclib often causes diarrhoea as a side effect, which can be quite common and occasionally severe. The onset of diarrhoea is most likely to occur within the first week of starting treatment and may persist for approximately two weeks.

It is important to consult with your healthcare team before smoking or drinking alcohol while on treatment, as it may lead to an increase in the amount of drug in your blood and worsen side effects. Smoking and drinking can also hinder the effectiveness of your treatment.

The out-of-pocket costs for patients with Medicare Part D coverage can fluctuate throughout the year based on the current phase of the Part D benefit. Approximately 70% of Verzenio prescriptions have a monthly cost ranging from $0 to $14, while the remaining prescriptions have an average monthly cost of $933.

Before using Verzenio, it is important to consult with your doctor if you have an ongoing infection, such as pneumonia. This is because Verzenio may weaken your immune system’s ability to fight infections, making it more difficult to treat the current infection.

According to the second interim analysis of the phase III MONARCH 3 trial, which involved 493 postmenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer, the combination of abemaciclib and a nonsteroidal aromatase inhibitor led to a median overall survival of 67.1 months. In comparison, patients who received endocrine therapy alone had a median overall survival of 54.5 months.

The study estimated the progression-free survival (PFS) for patients who experienced early onset of diarrhea or neutropenia compared to those who did not. The results showed that diarrhea was the most commonly reported adverse event (AE), with clinically significant diarrhea (grade ?2) reported in 42.8% of patients who were taking abemaciclib.

While taking abemaciclib, it is important to avoid consuming grapefruit or grapefruit juice as it can interfere with the effectiveness of the medication. If you happen to miss a dose, simply take the next one at your regular scheduled time and do not take a double dose.

The results of a clinical trial indicate that combining abemaciclib with endocrine therapy in patients with hormone receptor-positive, HER2-, node-positive early breast cancer, who are at high risk of recurrence, leads to a longer period of disease-free survival compared to using endocrine therapy alone.

Patients classified as high risk were identified as those who had either four or more pathologic axillary lymph nodes (pALN) or 1-3 pALN along with either a tumor grade of 3 or a tumor size of 50 mm or greater. Previously, abemaciclib was approved for this high-risk group, but it was also necessary for them to have a Ki-67 score of 20% or higher.

The doctors, nurses, and pharmacists are available to provide advice and answer any questions you may have regarding this treatment, which is generally well tolerated. It is important to be aware of potential side effects. One common side effect of Abemaciclib is diarrhea, which is typically most severe during the initial month of treatment.

Verzenio combined with fulvestrant resulted in a significant increase in overall survival for women compared to fulvestrant alone. According to a clinical study, women who received Verzenio plus fulvestrant had a median survival of 46.7 months, while those on fulvestrant alone had a median survival of 37.3 months, regardless of their menopausal status.

Verzenio, a non-chemotherapy oral tablet, is a targeted treatment called a CDK4 & 6 inhibitor. It is prescribed to adults for the treatment of a specific type of breast cancer.

Caution: Verzenio can result in significant adverse effects, such as severe diarrhea which may lead to dehydration or infection. Additionally, Verzenio often causes low white blood cell counts (neutropenia), increasing the risk of life-threatening infections.

Verzenio has the potential to suppress your immune system, which can heighten your susceptibility to infections. Prior to commencing Verzenio, your doctor will conduct tests to evaluate the functionality of your immune system. Additionally, they will regularly monitor your immune system throughout your Verzenio treatment.

Abemaciclib, Anastrozole, and Tamoxifen are available in oral tablet dosage forms. The brand names for these medications are Verzenio, Arimidex, and Soltamox, respectively.

Abemaciclib is a drug prescribed for the treatment of HR+ HER2- advanced or metastatic breast cancer. It works as an antitumor medication and acts as a dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6), which play a role in the cell cycle and the promotion of cancer cell growth when their activity is unregulated.

Eli Lilly and Company (NYSE: LLY) has announced that Verzenio (abemaciclib), when used in combination with standard adjuvant endocrine therapy (ET), has shown a significant 25% reduction in the risk of breast cancer recurrence compared to standard adjuvant ET alone. This is particularly beneficial for individuals with hormone-related breast cancer.

Hair loss or thinning may be observed after using abemaciclib due to factors unrelated to the drug. Malnutrition resulting from changes in appetite during cancer treatment, the natural aging process, and side effects of other medications could all contribute to hair changes.

You may experience symptoms such as nausea, vomiting, upset stomach, loss of appetite, weight loss, constipation, tiredness/weakness, headache, or changes in taste. If any of these symptoms persist or worsen, it is important to notify your doctor or pharmacist immediately. Additionally, diarrhea is a common side effect that can lead to dehydration.

Verzenio has the potential to cause serious inflammation of the lungs, which can be life-threatening and may result in death. If you experience any lung issues while taking Verzenio, your healthcare provider may advise you to temporarily discontinue the medication, reduce your dosage, or cease treatment altogether.

Please consult the table for potential side effects of abemaciclib. If you experience diarrhea, only take anti-diarrhea medication if prescribed by your healthcare team. Avoid consuming foods or drinks containing artificial sweeteners, as well as coffee and alcohol.

Mouth sores can be caused by any type of chemotherapy medicine, as well as certain targeted therapies such as Abemaciclib (Verzenio) and Trastuzumab (Herceptin).

During this treatment, it is possible for you to experience weight gain. However, maintaining a healthy diet and engaging in regular physical activity can assist you in maintaining a healthy weight. For further guidance, you can consult your doctor, nurse, or a dietitian.